© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Rafael Holdings, Inc. (RFL) stock surged +18.40%, trading at $1.93 on NYSE, up from the previous close of $1.63. The stock opened at $1.65, fluctuating between $1.63 and $2.06 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jun 09, 2026 | 1.65 | 2.06 | 1.63 | 1.93 | 566.85K |
| Jun 08, 2026 | 1.63 | 1.71 | 1.58 | 1.63 | 512.45K |
| Jun 05, 2026 | 1.39 | 1.69 | 1.39 | 1.55 | 413.33K |
| Jun 04, 2026 | 1.37 | 1.40 | 1.32 | 1.39 | 53.07K |
| Jun 03, 2026 | 1.32 | 1.37 | 1.30 | 1.35 | 50.79K |
| Jun 01, 2026 | 1.37 | 1.39 | 1.31 | 1.39 | 45.96K |
| May 29, 2026 | 1.37 | 1.38 | 1.34 | 1.37 | 39.9K |
| May 28, 2026 | 1.33 | 1.40 | 1.33 | 1.39 | 58.15K |
| May 27, 2026 | 1.32 | 1.37 | 1.32 | 1.37 | 29.99K |
| May 26, 2026 | 1.34 | 1.37 | 1.31 | 1.32 | 35.77K |
| May 22, 2026 | 1.30 | 1.35 | 1.30 | 1.34 | 15.16K |
| May 21, 2026 | 1.36 | 1.39 | 1.31 | 1.33 | 21.54K |
| May 20, 2026 | 1.35 | 1.39 | 1.29 | 1.37 | 37.26K |
| May 19, 2026 | 1.30 | 1.38 | 1.27 | 1.35 | 60.54K |
| May 18, 2026 | 1.26 | 1.32 | 1.26 | 1.29 | 36.99K |
| May 15, 2026 | 1.33 | 1.33 | 1.29 | 1.29 | 28.13K |
| May 14, 2026 | 1.34 | 1.39 | 1.28 | 1.31 | 82.94K |
| May 13, 2026 | 1.36 | 1.40 | 1.32 | 1.35 | 117.51K |
| May 12, 2026 | 1.37 | 1.37 | 1.30 | 1.33 | 53.31K |
| May 11, 2026 | 1.30 | 1.37 | 1.29 | 1.34 | 52.85K |
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
| Employees | 28 |
| Beta | 0.51 |
| Sales or Revenue | $917.00K |
| 5Y Sales Change% | -0.9% |
| Fiscal Year Ends | July |
| Sector | Real Estate |
| Industry | Real Estate - Services |